Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance in the next 6-12 months [1][5]. Core Views - The company reported a revenue of 806 million RMB for 2024, a decline of 33.32% year-on-year, and a net profit of 125 million RMB, down 55.01% year-on-year. The company plans to distribute a cash dividend of 0.49 RMB for every 10 shares [5]. - The report suggests that the risks associated with centralized procurement have gradually been released, and the company's valuation has reached a reasonable level, supporting a long-term positive outlook [5][9]. - The company has faced pressure from centralized procurement renewals, which have led to a decrease in product prices, impacting overall performance. However, the report anticipates that the effects of these pressures will gradually diminish [9][10]. Summary by Sections Financial Performance - The company’s main revenue is projected to recover to 937 million RMB in 2025, with a growth rate of 16.3%. The net profit is expected to increase to 153 million RMB, reflecting a growth rate of 22.1% [8]. - The report highlights a significant reduction in sales expenses, with a sales expense ratio of 25.80% in Q4 2024, down from 35.88% year-on-year and 40.56% quarter-on-quarter [9]. Research and Development - The company invested 133 million RMB in R&D in 2024, maintaining a high level of investment to enhance competitiveness. The focus is on new materials and product lines, including surgical robots and sports medicine [9][10]. Valuation Metrics - As of April 2, 2025, the company's total market capitalization is 58 billion RMB, with projected P/E ratios of 38.1 for 2025 and 31.8 for 2026 [9][10]. - The report indicates that the market has already priced in the pessimistic expectations regarding the company, suggesting that the current valuation is relatively low [9].

Investment Rating - The report maintains an "Accumulate" rating for the company [1][5] Core Views - The company has formed a product matrix in PC MCU and is consolidating its advantages in the HarmonyOS ecosystem through AIoT integration [3][8] - The company's revenue for 2024 is projected to be RMB 702 million, representing a year-on-year growth of 62.2% [7][8] - The net profit attributable to the parent company for 2024 is expected to be a loss of RMB 173 million, but this loss has narrowed by RMB 92 million compared to the previous year when excluding share-based payment impacts [8] Summary by Sections Stock Performance - The company's stock has shown an absolute increase of 20.8% year-to-date and 21.7% over the past 12 months [2] Financial Projections - Revenue projections for the upcoming years are as follows: - 2025: RMB 980 million (39.5% growth) - 2026: RMB 1,302 million (32.9% growth) - 2027: RMB 1,656 million (27.2% growth) [7][9] - The estimated EPS for 2025 is -0.73 RMB, with a gradual improvement expected by 2027 to 0.66 RMB [5][9] Business Performance - The MCU chip business revenue for 2024 is projected at RMB 326 million, a year-on-year increase of 68% [8] - The analog signal chain chip business is expected to see a revenue increase of 137% year-on-year, reaching RMB 181 million [8] - The AIoT chip business is projected to grow by 18% year-on-year, with revenue of RMB 182 million [8] Strategic Developments - The company is transitioning its MCU and ADC products towards high-end markets, with significant R&D investments [5][8] - The company has established a health big data cloud platform through its subsidiary, enhancing its position in the HarmonyOS ecosystem [8]

Investment Rating - The report maintains a rating of "Buy" for the company [2][4] Core Views - The company's gross margin is under pressure due to increased fixed costs from the Hefei production capacity and a deteriorating industry competitive landscape. However, the revenue share from AMOLED products continues to rise, and the company is actively expanding its non-display driver packaging business to create a second growth curve [2][7] Summary by Sections Financial Performance - The company reported a revenue of RMB 1.959 billion for 2024, representing a year-on-year growth of 20.3%. The gross margin was 31.3%, down by 4.4 percentage points year-on-year. The net profit attributable to the parent company was RMB 313 million, a decrease of 16% year-on-year [6][7] - For 2025, the estimated earnings per share (EPS) is adjusted to RMB 0.29, down by 25.6% from previous estimates. The projected PE ratios for 2025, 2026, and 2027 are 41.9, 37.4, and 33.2 respectively [4][6] Market Position and Strategy - The company is the leading provider of display driver chip packaging in China (excluding Hong Kong, Macau, and Taiwan) and ranks third globally. The revenue from display driver chip packaging is expected to reach RMB 1.758 billion in 2024, with AMOLED revenue accounting for over 20% of total revenue [7] - The company has innovated in the technology of copper-nickel-gold bumps, which allows for large-scale production and cost control. It is also expanding its non-display packaging capabilities, targeting power devices and Power ICs [7] Future Outlook - The company is expected to continue its revenue growth trajectory, with projected revenues of RMB 2.288 billion in 2025 and RMB 2.590 billion in 2026, reflecting growth rates of 16.8% and 13.2% respectively [6][8] - The gross margin is anticipated to decline further to 30.3% in 2025 and stabilize at 29.9% in 2026 and 2027 due to ongoing competitive pressures [8]

Investment Rating - The report maintains a "Buy" rating for the company [3][5]. Core Views - The company experienced short-term pressure on earnings, with a 2024 total revenue of RMB 7.31 billion, a decrease of 6.87% year-on-year, and a net profit attributable to shareholders of RMB 215 million, down 64.34% year-on-year. However, the fourth quarter showed a revenue increase of 15.10% year-on-year to RMB 2.12 billion and a net profit increase of 89.94% year-on-year to RMB 83 million [3][8]. - The company is expected to maintain its leading position in the industry of glyphosate and precision glyphosate, supported by scale effects and technological advantages, which will bolster future growth [3][5]. Financial Summary - The company’s revenue for 2024 is projected at RMB 7.31 billion, with a growth rate of -6.9%. The EBITDA is expected to be RMB 1.13 billion, and the net profit attributable to shareholders is forecasted to be RMB 215 million, reflecting a significant decline of 64.3% [7][11]. - The earnings per share (EPS) for 2025 is estimated at RMB 0.42, with corresponding price-to-earnings (PE) ratios of 21.2 times, 15.3 times, and 11.1 times for 2025, 2026, and 2027 respectively [5][11]. - The company plans to distribute a cash dividend of RMB 2 per 10 shares for 2024, resulting in a payout ratio of 74.34% [3][8]. Industry Context - The agricultural chemical industry is expected to remain under pressure in 2024, with glyphosate prices continuing to decline. The average price of glyphosate in 2024 is projected to be RMB 54,278 per ton, down 33.26% from 2023 [8]. - The domestic effective production capacity of glyphosate increased by 33.63% year-on-year to 151,000 tons in 2024, with an average operating rate of 62.86%, a slight decrease from the previous year [8].

Investment Rating - The report maintains a "Buy" rating for the company [1][5] Core Views - The company is experiencing steady revenue growth in 2024, but profitability has declined. New growth drivers include humanoid robots, AI/AR glasses, foldable screens, and server cooling solutions, supporting the "Buy" rating [3][8] Summary by Relevant Sections Financial Performance - In 2024, the company achieved revenue of RMB 44.211 billion, a year-on-year increase of 29.6%. However, the net profit attributable to the parent company decreased by 14.5% to RMB 1.753 billion. The gross margin was 15.8%, down 4.2 percentage points year-on-year [7][8] - The company expects earnings per share (EPS) of RMB 0.34, RMB 0.47, and RMB 0.56 for 2025, 2026, and 2027, respectively, with corresponding price-to-earnings ratios of 26.6x, 19.3x, and 16.1x [5][7] Revenue Breakdown - The AI terminal segment generated revenue of RMB 40.73 billion in 2024, up 32.8% year-on-year, but the gross margin fell by 4.4 percentage points to 17.4%. Key growth areas include sensors and related modules, as well as imaging display products, both exceeding 100% growth [8] - The automotive and low-altitude economy sectors contributed RMB 2.12 billion in revenue, a 52.9% increase year-on-year. However, the clean energy business saw a 25% decline in revenue to RMB 1.17 billion due to a significant reduction in customer orders [8] Growth Drivers - The company is making progress in humanoid robots, AI/AR glasses, foldable screens, and server-related businesses. For instance, the humanoid robot segment is expected to enter mass production in 2025, with a gross margin of approximately 60% [8] - The AI/AR glasses and XR wearable devices are anticipated to grow rapidly with the upcoming release of new products in 2025. The foldable screen products have already seen significant shipments, and the server business has begun to penetrate customer supply chains [8]

计算机 | 证券研究报告 — 调整盈利预测 2025 年 4 月 3 日 301153.SZ 买入 原评级：买入 市场价格:人民币 26.54 板块评级:强于大市 本报告要点 2024 年中科江南毛利率同比提升，与华为 深化合作有望打开公司新成长空间。 jingwen.zheng@bocichina.com 证券投资咨询业务证书编号：S1300525010001 股价表现 (%) 今年 至今 1 个月 3 个月 12 个月 绝对 2.1 (6.8) (5.0) (57.9) 相对深圳成指 (2.0) (5.8) (5.9) (66.8) 发行股数 (百万) 349.92 (51%) (37%) (23%) (9%) 5% 19% Apr-24 May-24 Jun-24 Jul-24 Aug-24 Sep-24 Oct-24 Nov-24 Dec-24 Jan-25 Feb-25 Mar-25 中科江南 深圳成指 | 流通股 (百万) | | 205.87 | | --- | --- | --- | | 总市值 (人民币 百万) | | 9,286.88 | | 3 个月日均交易额 (人民币 百万) | | ...

Investment Rating - The report assigns an "Accumulate" rating to the company, marking its first coverage with a positive outlook on the stock [1]. Core Views - The company is recognized as a leading domestic OLED terminal materials enterprise, benefiting from increasing downstream demand and the rising domestic production rate of OLED materials, which presents significant growth opportunities [1][6]. Summary by Sections Company Overview - The company specializes in the research, production, and sales of OLED organic materials, including OLED terminal materials and intermediates. It has achieved breakthroughs in domestic production and is one of the few companies capable of mass-producing OLED terminal materials [9][16]. Financial Performance - The company reported a revenue of RMB 472 million in 2024, representing a year-on-year growth of 56.9%. The net profit attributable to shareholders is projected to be RMB 167 million, with a significant increase of 116.7% [8][20]. Market Demand and Growth - The demand for OLED materials is expected to grow continuously due to the increasing penetration of OLED panels and the expansion of application scenarios. The domestic market for OLED organic materials is projected to reach RMB 4.3 billion in 2023, with a compound annual growth rate (CAGR) of 11% expected until 2030 [9][38]. Competitive Advantages - The company has a strong R&D capability, a comprehensive product line, and established relationships with major domestic panel manufacturers such as BOE and Huaxing. Its integrated production capabilities across the OLED supply chain enhance its competitive edge [9][17]. Valuation and Earnings Forecast - The report forecasts the company's net profits for 2024, 2025, and 2026 to be RMB 167 million, RMB 308 million, and RMB 459 million, respectively, with corresponding earnings per share (EPS) of RMB 0.41, RMB 0.77, and RMB 1.14 [6][8].

Investment Rating - The report maintains a rating of "Buy" for the company [1][3][5] Core Views - The company reported a revenue of RMB 284.42 billion for 2024, representing a year-on-year growth of 10.07%, and a net profit attributable to shareholders of RMB 10.17 billion, an increase of 23.51% year-on-year [1][4][5] - The recovery of domestic consumption is expected to drive logistics demand, while the company is actively expanding into international markets to seek additional growth opportunities [1][4][5] - The forecast for net profit attributable to shareholders for 2025-2027 is RMB 11.78 billion, RMB 13.61 billion, and RMB 15.67 billion, respectively, with year-on-year growth rates of 15.9%, 15.5%, and 15.1% [1][5][4] Summary by Sections Financial Performance - In 2024, the company achieved a revenue of RMB 284.42 billion and a net profit of RMB 10.17 billion, marking a significant milestone as the net profit exceeded RMB 10 billion for the first time [4][3] - The gross margin improved to 13.9%, up by 1.11 percentage points, and the net profit margin increased to 3.59%, up by 0.53 percentage points [4][5] Business Segments - The express logistics segment generated revenue of RMB 205.78 billion, growing by 7.66% year-on-year, while the supply chain and international segments saw a revenue increase of 17.53% to RMB 70.49 billion [4][5] - The growth in traditional business segments was supported by the expansion of express delivery services and the penetration into county-level markets for same-city delivery [4][5] Future Outlook - The company's future performance is expected to be driven by the gradual recovery of domestic consumption and the progress of international market expansion [5][4] - The earnings per share (EPS) for 2025-2027 are projected to be RMB 2.36, RMB 2.73, and RMB 3.14, respectively, with corresponding price-to-earnings (P/E) ratios of 18.2, 15.8, and 13.7 [5][4]

强大于市 房地产行业第 13 周周报（2025 年 3 月 22 日-2025 年 3 月 28 日） 本周新房成交面积同比转负、二手房成交面积同比涨幅 收窄；土拍溢价率同环比均提升 新房成交面积环比涨幅扩大，同比由正转负。二手房成交面积同环比涨幅均收窄；新房库存面 积同环比均下降，去化周期同环比均下降。 核心观点 政策 本周，佛山发布房地产融资白名单新规，指导符合条件项目"能报尽报"，确保资金拨付"能 早尽早"；深圳出台城市更新新规，加强统筹规划，审慎新增更新单元计划，清理无效项目， 完善融资支持、税收优惠及安置补偿政策，推动存量项目落地；安徽发布《推动经济持续 回升向好细化政策举措》，推行"房票"等货币化安置方式，引导企业建设"好房子"；青岛首 批配售型保障房于 3 月 27 日启动选房，共涉及 3613 套房源；安达市、岳阳市分别公布《安 达市保障性住房工作实施方案》和《岳阳市配售型保障性住房管理办法（征求意见稿）》。 投资建议 风险提示 房地产行业 | 证券研究报告 — 行业周报 2025 年 4 月 2 日 房地产调控升级；销售超预期下行；融资收紧。 相关研究报告 《70 城房价环比跌幅持续收窄，一 ...

Investment Rating - The report maintains a "Buy" rating for the company, with a previous rating also being "Buy" [1][6]. Core Views - The company has shown significant growth in revenue and net profit for 2024, driven by the launch of several high-frequency, high-resolution bridge chip products and accelerated development in automotive electronics [4][9]. - The company is actively expanding into high-performance computing (HPC) and high-speed communication chip sectors, indicating a positive operational outlook [4][9]. Financial Summary - The company’s revenue for 2024 is projected to be RMB 466 million, representing a year-on-year growth of 44.2%. The net profit attributable to the parent company is expected to reach RMB 144 million, a 40.6% increase [8][9]. - The company’s earnings per share (EPS) for 2025 is estimated at RMB 2.04, with a corresponding price-to-earnings (P/E) ratio of 55.5 [6][8]. - The company’s EBITDA for 2024 is projected at RMB 133 million, with a growth rate of 61.9% [10]. Product Development and Market Position - The company has launched multiple new products in 2024, including high-resolution chips that support 4K@144Hz resolution and various automotive applications [9]. - The automotive chip and system solutions division was established at the end of 2024, aiming to enhance the company’s position in the automotive SerDes market [9]. Growth Drivers - The semiconductor industry recovery has led to increased demand from downstream customers, contributing to the company's strong revenue growth [9]. - The company’s R&D expenses have increased significantly, reaching nearly RMB 100 million in 2024, which is 21.5% of its revenue, indicating a strong commitment to innovation [9].